Skip to content

Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix

Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06335628
Enrollment
38
Registered
2024-03-28
Start date
2024-08-28
Completion date
2030-04-01
Last updated
2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective Tissue Graft, Volume Collagen Matrix Xenograft

Brief summary

The aim of this research project is to compare two surgical procedures to improve soft tissue volume. Both procedures have already been validated, but despite their great clinical relevance, little data exists in the literature. With this study, the investigators aim to evaluate volumetric changes of connective tissue graft versus biomaterial (membrane). In addition, further clinical measurements will be taken and patient satisfaction will be assessed.

Interventions

DEVICEGeistlich Fibro-Gide®

Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.

Sponsors

University of Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Informed Consent signed by the subject * Age ≥ 18 years * Willingness to sign informed consent and to participate in the study * Single tooth gap or extended edentulous space in the lower or posterior jaw including a pontic site with a soft tissue deficiency. * Tooth gap of ≥ 8 mm. * Presence of natural or artificial opposing dentition * Sufficient vertical interocclusal space of an implant restoration (7mm) * Bounded by natural and periodontally stable teeth * Treatment plan must include tooth replacement with an implant or tooth-supported fixed dental prosthesis.

Exclusion criteria

* Any physical or mental disorder that would interfere with the ability to perform adequate oral hygiene or the capability of providing written informed consent and compliance with the protocol * Severe bruxism, clenching habits, or presence of oro-facial pain * Uncontrolled diabetes mellitus (HbA1c \>7.0) * Clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) * Any active oral or systemic acute infections * Currently receiving chemo- or radiotherapy or a history of radiotherapy in the head and neck area * Severe hematologic disorders * Any other diseases or medications that may compromise normal wound healing * Pregnancy or nursing mother * Contraindications and limitations of the MD as described in the instructions for use: during pregnancy or lactation, children, presence of acute infection in the surgical area, patients with known sensitivity to porcine material or collagen allergies. * Vulnerable subjects * Known or suspected non-compliance * Drug or alcohol abuse * Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. * Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation, * Enrolment of the PI, his/her family members, employees and other dependent persons

Design outcomes

Primary

MeasureTime frameDescription
Volumetric dimensional changes0-5 yearsTo assess the volumetric dimensional changes in pontic sites after site development using CTG compared to VCMX

Secondary

MeasureTime frameDescription
Clinical: PPD0-5 yearsClinical: Probing depth in neighboring teeth
Clinical BoP0-5 yearsClinical: Bleeding on probing
Clinical: Suppuration0-5 yearsClinical: Suppuration on probing
Clinical: Mucosa0-5 yearsClinical: Apical migration of the marginal mucosa
Clinical: ktw0-5 yearsClinical: Keratinized tissue width
Clinical: Mobility0-5 yearsClinical: Mobility
Clinical: Thickness0-5 yearsClinical: Mucosal thickness
Clinical: Contributing factors0-5 yearsClinical: Presence of local contributing factors
Patient-reported satisfaction0-5 yearsQuestionnaire: Overall patient satisfaction with the treatment provided
Patient-reported esthetics0-5 yearsQuestionnaire: Esthetics
Patient-reported discomfort0-5 yearsQuestionnaire: Discomfort
Patient-reported pain0-5 yearsQuestionnaire: Pain
Prosthetics Survival0-5 yearsProsthetic-related: Fixed dental prostheses survival rates
Prosthetics Success0-5 yearsProsthetic-related: Fixed dental prostheses success rates
Prosthetics Complications0-5 yearsProsthetic-related: Technical complications
Prosthetics PES-WES0-5 yearsProsthetic-related: Esthetic score (PES-WES)
Prosthetics: Occlusal0-5 yearsProsthetic-related: Occlusal contacts (static and dynamic)
Prosthetics: Interproximal0-5 yearsProsthetic-related: Presence of interproximal contacts.
Radiographics BL0-5 yearsMarginal bone levels
Radiographics PP0-5 yearsPeriapical pathosis
Radiographics distance0-5 yearsDistance from the adjacent teeth/implants
Radiographics Contacts0-5 yearsPresence of open contacts

Countries

Switzerland

Contacts

CONTACTManrique Fonseca, DDS
manrique.fonseca@unibe.ch+41316840630
PRINCIPAL_INVESTIGATORManrique Fonseca, DDS

University of Bern

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026